The Medicare GLP-1 Bridge Program Launch: What You Need to Know

July 1, 2026 marked the official launch of the Medicare GLP-1 Bridge Program. For the first time, Medicare is providing a pathway to affordable, dedicated weight-loss medications for eligible beneficiaries. If you are enrolled in Medicare, this pilot program could significantly lower your out-of-pocket costs for popular weight management treatments. Let’s break down the answers to the most common questions about how the program works.

1. Do I qualify for the Medicare GLP-1 Bridge Program?

To enroll, you must be registered in a Medicare Part D plan and meet the criteria for one of three distinct qualification pathways:

• Pathway 1: A starting Body Mass Index (BMI) of 35 or higher.

  • Note: This includes your BMI before you begin treatment. If you have been paying out-of-pocket and have already lost significant weight, you can still qualify based on your baseline numbers.

• Pathway 2: A starting BMI of 30 or higher, plus at least one of these conditions:

  • Heart failure

  • Chronic kidney disease

  • Significant high blood pressure requiring 2 or more daily medications

• Pathway 3: A starting BMI of 27 or higher, plus at least one of these conditions:

  • Prediabetes

  • History of a heart attack or stroke

  • Symptomatic peripheral artery disease (PAD)

 Important Exclusions: You will not be eligible for this specific Bridge Program if you have an existing diagnosis of type 2 diabetes or severe obstructive sleep apnea. If you have either of these diagnoses, your GLP-1 medication should already be evaluated for coverage under your standard Medicare prescription drug benefits rather than this pilot program.

2. Which medications are covered?

The program covers specific brand-name weight-loss drugs:

• Wegovy® (weekly injection or daily oral pill)

• Zepbound® (KwikPen® weekly injection formulation only—vials and single-dose pens are excluded)

• Foundayo® (daily oral pill)

3. What is the out-of-pocket cost?

If you meet the prior authorization requirements, your cost is a flat $50 copay for a 1-month (30-day) supply. Please note that multi-month fills (such as 60-day or 90-day supply scripts) are not permitted or covered under the Bridge Program rules.

4. How long will this program be available?

The Medicare GLP-1 Bridge Program is a temporary demonstration project. Funding and operations are currently scheduled to run through December 31, 2027.

Overall, we are incredibly pleased to see this vital program expanding access to those who truly need it. By making these highly effective medications more affordable and attainable, eligible beneficiaries can finally experience the profound health benefits and risk reductions in chronic diseases that these treatments offer.